| 1 |
15319248 | Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma. | 2004 Sep |
1 |
| 2 |
12171880 | A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. | 2002 Aug |
1 |
| 3 |
12435817 | Identification of PKCalpha isoform-specific effects in cardiac myocytes using antisense phosphorothioate oligonucleotides. | 2002 Dec |
1 |
| 4 |
11723237 | Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-alpha (Isis 3521) and antisense bcl-2 (G3139) phosphorothioate oligodeoxynucleotides: relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells. | 2001 Dec |
1 |
| 5 |
11890365 | ISIS-3521. Isis Pharmaceuticals. | 2001 Oct |
1 |
| 6 |
9665591 | Apoptosis is induced in glioma cells by antisense oligonucleotides to protein kinase C alpha and is enhanced by cycloheximide. | 1998 Jun 1 |
1 |
| 7 |
9203625 | Antisense oligonucleotides targeting human protein kinase C-alpha inhibit phorbol ester-induced reduction of bradykinin-evoked calcium mobilization in A549 cells. | 1997 Feb |
1 |